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Aim: In this study, the curative effect of valsartan on hypertension based on its effect on visfatin levels and lipid profiles was investigated.
Materials and methods: Forty patients aged 38–60 with hypertension were included in the study. In order to determine initial visfatin
levels and lipid profiles, blood samples were taken from the patients and all were started on 80-mg valsartan tablets. All patients were
monitored for 12 weeks.
Results: By using multivariate regression analysis, it was determined that visfatin levels affected systolic blood pressure (SBP) (P =
0.012, beta; –0.43, 95% CI: –0.092 to –0.012). After the patients received the valsartan treatment for 12 weeks, a significant increase in
visfatin levels was observed (pre- and posttreatment, respectively: 0.42 ± 0.22 ng/mL and 0.71 ± 0.36 ng/mL, P < 0.001). When the lipid
profile changes of patients were examined, only low-density lipoprotein (LDL) levels showed a statistically significant change (pre- and
posttreatment, respectively: 150.32 ± 13.22 mg/dL and 143.82 ± 7.53 mg/dL, P = 0.008).
Conclusion: In this study, it was found that visfatin levels affected SBP in newly diagnosed hypertensive patients and valsartan treatment
increased visfatin levels. In addition, the use of valsartan reduced LDL levels.
Key words: Hypertension, valsartan, visfatin, lipid, multivariate regression analysis

1. Introduction
Hypertension is an important health problem that many
people face at some point in their lives. Its prevalence differs
based on geographic, cultural, demographic, nutritional,
and genetic factors, and it is one of the most important
health problems in developed countries. Hypertension has
been accepted as one of the most important modifiable
risk factors contributing to an increased risk of coronary
artery disease and it can also damage the structure and
function of organs when it is not controlled well (1,2).
The endothelium is a dynamic organ with a complex
structure that can secrete and synthesize vasodilator and
vasoconstrictor substances in response to environmental
stimulation. In endothelial dysfunction, the balance of
vasoactive substances is damaged and complications occur
with the vascular structure and function (3). Consequently,
by causing an increase in vascular resistance and damage,
* Correspondence: cipro0055@yahoo.com

endothelial dysfunction has an important role in vascular
pathogenesis, which is responsible for hypertension (4).
Visfatin, a recently discovered type of adipokine,
sustains vascular dysfunction by causing vascular smooth
muscle inflammation in some metabolic diseases (5).
A relationship has been shown between the classic
cardiovascular disease risk factors (cholesterol, smoking,
hypertension, diabetes mellitus, and obesity) and increased
visfatin levels (6).
Although paradoxical results have been obtained from
research on the treatment of endothelial dysfunction
with antihypertensive drugs, many studies have reported
important improvements in endothelial function with
antihypertensive treatment in hypertensive individuals (4).
As a result, the decision to use drugs for antihypertensive
treatment, thus bringing about a decrease in blood pressure
and an improved efficiency of endothelial functions, is a
rational approach.
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This research study was mainly concerned with
observing the changes in serum visfatin levels as a result
of valsartan treatment in newly diagnosed hypertensive
patients. Moreover, the effects of valsartan treatment on
lipid profiles were observed.
2. Materials and methods
2.1. Study population
Forty patients newly diagnosed with hypertension stage
1 (according to the Seventh Report of the Joint National
Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure), who visited the
Gülhane Military Medical Faculty Internal Medicine
Outpatient Clinic between January 2010 and July 2010 and
had not previously used any antihypertensive treatment,
were included in this study. Patients with a history of
secondary hypertension, renal dysfunction, diabetes, acute
infection, polycystic ovary syndrome, preeclampsia, or
other systemic illnesses were excluded. After the patients
were diagnosed with hypertension, blood was drawn for
fasting blood glucose (FBG), high-density lipoprotein
(HDL), low-density lipoprotein (LDL), total cholesterol
(TC), triglyceride (TG), and serum visfatin levels. This
research received approval from the Pharmaceutical Ethics
Committee.
2.2. Drug administration
All patients were given a daily dose of 80 mg of valsartan
orally and their adaptation to the treatment was monitored.
The dose of valsartan was increased to 160 mg if needed.
The patients were observed for 12 weeks; at the end of this
period the observed parameters were measured again and
changes were noted.
2.3. Determination of visfatin levels
Visfatin levels were measured from sera separated by
centrifugation (10 min at 4000 rpm) from whole venous
blood drawn in the morning after overnight fasting. Serum
samples were kept at –80 °C until the measurements were
performed and visfatin measurements were done at the
same time for all the samples. The measurement of visfatin
levels was done using the immunoassay method with a
human quantitative visfatin enzyme immunoassay kit and
a Bio-Tek reader.
2.4. Statistical analysis
Statistical evaluations of data were done using SPSS 15.0
with the help of a microchip. The differences between
the groups were analyzed according to group numbers
and data distribution with Student’s t-test or the Mann–
Whitney U test. Multivariate regression analysis was done
for determining the relationship between visfatin levels
and biochemical parameters. The data were calculated as
mean ± standard deviation, median (min–max), beta, and
95% confidence interval (CI). P values less than 0.05 were
accepted as valid in all the tests.
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3. Results
Forty newly diagnosed hypertensive patients, 14 males
(35%) and 26 females (65%), were included in the study.
The sociodemographic characteristics and visfatin levels
of the patients according to sex are shown in Table 1.
There were no statistical differences observed in terms
of height, weight, age, body mass index (BMI), systolic
blood pressure (SBP), diastolic blood pressure (DBP), and
visfatin levels (P > 0.05 for all parameters) based on sex.
Visfatin levels affected SBP according to the
multivariate regression analysis (P = 0.012, beta: –0.43,
95% CI: –0.092 to –0.012). A similar effect was not found
for DBP, FBG, TC, HDL, or LDL levels, or for BMI (P >
0.05 for all parameters) (Table 2).
The blood pressure, visfatin, and lipid profile values
of the patients who were given valsartan treatment from
the time of diagnosis and after treatment are shown in
Table 3. Visfatin levels were elevated in patients who used
valsartan (pre- and posttreatment, respectively: 0.42 ± 0.22
ng/mL and 0.71 ± 0.36 ng/mL, P < 0.001). A meaningful
decrease was determined for LDL level when the effects
of valsartan treatment were observed on the lipid profile
(pre- and posttreatment, respectively: 150.32 ± 13.22 mg/
dL and 143.82 ± 7.53 mg/dL, P = 0.008). However, there
were no similar findings for the levels of HDL, TC, and
TG (P > 0.05 for all parameters). As expected, there were
meaningful decreases in SBP and DBP after the valsartan
treatment (P < 0.001 for each parameter) (Table 3).
4. Discussion
In this study, visfatin levels affected SBP in newly
diagnosed hypertensive patients and valsartan treatment
increased visfatin levels. In addition, the use of valsartan
reduced LDL levels.
Currently, the topic of adipose tissue that works like
an endocrine organ by secreting bioactive substances
has drawn the attention of scientists. These substances
whose origins are in adipose tissue take a part in energy
hemostasis and inflammation. Visfatin, which is one of
these substances, also plays a role in vascular damage and
endothelial dysfunction (7). Visfatin was investigated in
many cardiovascular diseases; visfatin levels were found
to be low in some and high in others. We observed that
visfatin levels in this study were similar to the levels seen
linked to cardiovascular disease (8–11).
Although visfatin is generally produced from visceral
fat tissue and its high circulation levels are related to
obesity, there is some doubt about whether the criteria that
evaluate obesity have been emphasized (9). Even though
Chen et al. found a positive relationship between visfatin
levels and waist-to-hip ratio, they did not confirm a similar
relationship for visfatin and BMI (12). In other studies, no
relationship was shown between visfatin and waist-to-hip
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Table 1. Sociodemographic characteristics, SBP, DBP, and visfatin levels of patients participating in the study.
Parameters

Number

Average

Women

26

166.88 ± 3.31

Men

14

168.85 ± 2.87

Women and men

40

167.10 ± 6.48

Women

26

72.57 ± 3.46

Men

14

74.14 ± 3.05

Women and men

40

73.20 ± 6.35

Women

26

47 (38–58)

Men

14

48 (43–60)

Women and men

40

48 (38–60)

Women

26

26.08 ± 1.51

Men

14

26.01 ± 1.08

Women and men

40

26.06 ± 2.15

Women

26

149.40 ± 3.62

Men

14

149.80 ± 3.85

Women and men

40

149.55 ± 3.67

Women

26

93.40 ± 3.45

Men

14

93.87 ± 2.53

Women and men

40

93.57 ± 3.11

Women

26

0.41 ± 0.15

Men

14

0.44 ± 0.29

Women and men

40

0.42 ± 0.22

P

Height, cm
NS a

Weight, kg
NS a

Age, years
NS b

BMI, kg/m2
NS a

SBP, mmHg
NS a

DBP, mmHg
NS a

Visfatin, ng/mL
NS a

Data are presented as mean ± standard deviation for the parametric tests and median (min–max) value for the
nonparametric tests and numbers. NS = nonsignificant, a = unpaired Student’s t-test, b = Mann–Whitney U test,
and BMI = body mass index. There were no differences in the sociodemographic properties of the patients based
on sex.
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Table 2. Multivariate regression analysis between visfatin levels and SBP, DBP, FBG, TG, TC, HDL, LDL, and BMI.

Visfatin

SBP

DBP

FBG

TG

TC

HDL

LDL

BMI

P

0.012

NS

NS

NS

NS

NS

NS

NS

beta

–0.43

0.04

–0.07

–0.26

0.11

0.09

–0.15

0.03

95% CI

–0.092 to
–0.012

–0.042 to
0.054

–0.025 to
0.016

–0.003 to
0.001

–0.005 to
0.008

–0.014 to
0.024

–0.009 to
0.005

–0.042 to
0.05

SBP = systolic blood pressure, DBP = diastolic blood pressure, FBG = fasting blood glucose, HDL= high density lipoprotein, LDL = low
density lipoprotein, BMI = body mass index, and NS = nonsignificant (P > 0.05). Visfatin levels only affected SBP.
Table 3. Changes in SBP, DBP, lipid profile, and visfatin levels with valsartan treatment.
Parameters

At diagnosis

At 12th week

P

TC, mg/dL

195.20 ± 10.42

191.50 ± 12.99

NS a

LDL, mg/dL

150.32 ± 13.22

143.82 ± 7.53

0.008 a

HDL, mg/dL

40.37 ± 3.11

40.22 ± 3.10

NS a

TG, mg/dL

186.52 ± 11.22

179.42 ± 20.58

NS a

SBP, mmHg

147.78 ± 1.27

124.80 ± 4.54

< 0.001 a

DBP, mmHg

96.20 ± 1.38

83.30 ± 2.04

< 0.001 a

Visfatin, ng/mL

0.42 ± 0.22

0.71 ± 0.36

< 0.001 a

Data are presented as mean ± standard deviation for the parametric tests. NS = nonsignificant (P > 0.05), a =
paired Student’s t-test, TC = total cholesterol, LDL = low density lipoprotein, HDL = high density lipoprotein,
TG = triglyceride, SBP = systolic blood pressure, and DBP = diastolic blood pressure. LDL, SBP, DBP, and
visfatin levels were significantly changed by the valsartan treatment.

ratio or BMI (9,13,14). In the studies by Berndt et al. and
Taskesen et al., a relationship was found between plasma
visfatin levels and BMI (15,16); however, in this study a
relationship was not found between plasma visfatin levels
and BMI.
In their study, Saddi-Rosa et al. determined that
variations in the visfatin gene might affect glucose,
lipid, and other metabolic and vascular events and can
cause changes in visfatin levels (17). No relationship
between visfatin levels and TC, HDL, LDL, or TG
was determined in the study by Kadoglou et al. with
coronary artery patients or the study by Dogru et al. with
newly diagnosed young hypertensive patients without
complications (9,18,19). Some studies showed that there
is a strong relationship between visfatin levels and lipid
parameters (20,21). In this study, a relationship between
visfatin levels and lipid profile was not determined. For
this reason, our study is similar to those of Kadoglou et
al. and Dogru et al.
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In this study, visfatin levels affected only SBP, regardless
of other parameters. It is interesting that a similar effect on
DBP was not detected.
Although there are currently many drugs affecting
a multitude of different mechanisms in hypertension
treatment, hypertension still retains its importance as a
serious societal health problem. Antihypertensive drugs not
only reduce blood pressure but also have a role in metabolic
movements. This study observed the effects of valsartan,
a type of AT-II receptor blocker (ARB), on visfatin levels
as a new marker of vascular damage physiopathology.
Storka et al. showed that the use of ARBs, angiotensinconverting enzyme inhibitors, and rosiglitazone increases
the visfatin levels of patients with type 2 diabetes mellitus
(22). In their research done on hypertensive patients with
metabolic syndrome, Saraç et al. found that telmisartan
decreases and valsartan increases visfatin levels, but these
changes were not statistically significant (23). However, in
this study we confirmed that valsartan treatment increases
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visfatin levels. ARBs show their effects on visfatin secretion
via binding to peroxisome proliferator-activated receptor
gamma (PPAR) receptors with agonistic interaction.
Therefore, visfatin levels increase via a PPAR-dependent
pathway (22). The demonstrated effect of valsartan on
visfatin levels is coherent with the literature.
Hypertension is not only a marker of cardiovascular
damage but also a traditional risk factor for atherosclerosis
related to age, sex, obesity, smoking, diabetes mellitus, and
dyslipidemia. Antihypertensive drugs show their effects
on the cardiovascular system not only by decreasing
blood pressure but also by reducing metabolic diseases
like hyperlipidemia. The use of high doses of diuretics and
beta-blockers causes an increase in TC and TG levels and
a decrease in HDL levels (24,25). Despite the studies that
show losartan stays metabolically neutral from ARBs, some
research shows that it provides healing for the lipoprotein
profile (26,27). A definitive determination has not yet been
made regarding the effects of ARBs on lipid metabolism.
Therefore, this study’s purpose was to research the effect
of valsartan, an ARB, on the lipid profile. Trenkwalder et
al. showed that candesartan, another ARB, had no effect
on lipid profile in patients with type 2 diabetes mellitus
or mild hypertension (28). However, some positive results
were found in research on the effects on losartan on lipid
profile (27,29,30). In the broad study by Kyvelou et al.
that researched the effect of ARBs on the lipid profiles of
untreated patients with no complications, patients that
received candesartan had a decrease in total cholesterol
and LDL levels, but the patients that received losartan and
valsartan only had a decrease in triglyceride levels (31). In

the research by Hanefeld et al. on the effect of valsartan
treatment on lipid profile in mildly or severely hypertensive
patients, it was noted that valsartan decreased TC and LDL
levels but did not cause any changes in HDL or triglyceride
levels (32). According to Barutçuoğlu et al., telmisartan
therapy, acting as a partial PPARγ agonist, did not affect
serum TC, TG, HDL, or LDL concentrations (33). In
this study, a meaningful decrease was observed only in
LDL levels. When the results of this study are compared
to other research done on hypertensive patients who
received the same drug therapy, similar decreases were
observed. It should not be overlooked that ARB usage
with hypertensive patients generally causes healing in the
lipid profile, and so especially for patients with metabolic
syndrome, it is a good alternative therapy.
In this study, no side effects were observed in the
patients who received valsartan therapy, and it was well
tolerated. Previous research has shown that valsartan
can be tolerated well and used safely, and it is similar to a
placebo in terms of side effects (27,34). Our study shows
similar findings with earlier studies that were done to
determine side effects.
We think that when this study is done with a
randomized control and over a longer period, it will be
more useful in terms of evaluating the effects of valsartan
on visfatin levels over the long term.
Visfatin, an adipokine, has a role in endothelial
dysfunction and increases with valsartan therapy. It is
noted that valsartan can provide effective blood pressure
control and have positive effects on lipid profiles as well as
being well tolerated in terms of side effects.

References
1.

Karamahmutoğlu F. Dirençli Hipertansiyonun Vücut Kitle
İndeksi ile İlişkisi. Uzmanlık Tezi. Okmeydani Eğitim ve
Araştırma Hastanesi, 1. Dahiliye Kliniği; 2007.

2.

Bostan M, Şatıroğlu Ö, Uydu HA, Çicek Y, Çanga A, Karadağ
Z et al. Distribution of coronary artery risk factors: a regional
analysis. Turk J Med Sci 2011; 41: 317–24.

3.

Cai H, Harrison DG. Endothelial dysfunction in cardiovascular
diseases. Circ Res 2000; 87: 840–4.

4.

Kırkpantur A, Altun B. Endotel disfonksiyonu ve hipertansiyon.
Türk J Cardiol 2006; 9: 55–61.

5.

6.

7.

Wozniak SE, Gee LL, Watchel MS, Frezza EE. Adipose tissue:
the new endocrine organ? Dig Dis Sci 2009; 54: 1847–56.

8.

Yilmaz MI, Saglam M, Carrero JJ, Quereshi AR, Caglar
K, Eyileten T et al. Serum visfatin concentration and
endothelial dysfunction in chronic kidney disease. Nephrol
Dial Transplant 2008; 23: 959–65.

9.

Dogru T, Sonmez A, Tasci I, Yilmaz MI, Erdem G, Erturk
H et al. Plasma visfatin levels in young male patients with
uncomplicated and newly diagnosed hypertension. J Hum
Hypertens 2007; 21: 173–5.

Romacho T, Azcutia V, Vazquez-Bella M, Matesanz N, Cercas
E, Nevado J et al. Extracellular PBEF/NAMPT/visfatin activates
pro-inflammatory signalling in human vascular smooth
muscle cells through nicotinamide phosphoribosyltransferase
activity. Diabetologia 2009; 52: 2455–63.

10.

Grill S, Rusterholz C, Zanetti-Dallenbach R, Tercanli S,
Holzgreve W, Hahn S et al. Potential markers of preeclampsia –
a review. Reprod Biol Endocrinol 2009; 7: 70–84.

11.

Arner P. Editorial: Visfatin – a true or false trail to type 2
diabetes mellitus. J Clin Endocrinol Metab 2006; 91: 28–30.

Liu SW, Qiao SB, Yuan JS, Liu DQ. Association of plasma
visfatin levels with inflammation, atherosclerosis and acute
coronary syndromes (ACS) in humans. Clin Endocrinol (Oxf)
2009; 71: 202–7.

12.

Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin
SJ et al. Elevated plasma level of visfatin/pre-B cell colonyenhancing factor in patients with type 2 diabetes mellitus. J
Clin Endocrinol Metab 2006; 91: 295–9.

61

ATACAN et al. / Turk J Med Sci
24.

Lardinois CK, Neuman SL. The effects of antihypertensive
agents on serum lipids and lipoproteins. Arch Intern Med
1988; 148: 1280–8.

25.

Grimm RG, Leon AS, Hunning DB, Lenz K, Hannan P,
Blackburn H. Effects of thiazide diuretics on blood lipids and
lipoproteins in mildly hypertensive patients: a double-blind
controlled trial. Ann Intern Med 1981; 94: 7–11.

26.

Moan A, Hoieggen A, Seljeflot I, Risanger T, Arnesen H,
Kjeldsen SE. The effect of angiotensin II receptor antagonism
with losartan on glucose metabolism and insulin sensitivity. J
Hypertens 1996; 14: 1093–7.

Taskesen D, Kirel B, Us T. Serum visfatin levels, adiposity and
glucose metabolism in obese adolescents. J Clin Res Pediatr
Endocrinol 2012; 4: 75–9.

27.

Ogihara T, Yoshinaga K. The clinical efficacy and tolerability
of the angiotensin II receptor antogonist losartan in Japanese
patients with hypertension. Blood Press 1996; 5: 78–81.

17.

Saddi-Rosa P, Oliveira CSV, Giuffrida FM, Reis AF. Visfatin,
glucose metabolism and vascular disease: a review of evidence.
Diabetol Metab Syndr 2010; 2: 21.

28.

18.

Kadoglou NP, Gkontopoulos A, Kapelouzou A, Fotiadis G,
Theofilogiannakos EK, Kottas G et al. Serum levels of vaspin
and visfatin in patients with coronary artery disease – Kozani
study. Clinica Chimica Acta 2011; 412: 48–52.

Trenkwalder P, Mehtovirta M, Dahl K. Long-term treatment
with candesartan cilexetil does not affect glucose hemostasis or
serum lipid profile in mild hypertensives with type II diabetes.
J Hum Hypertens 1997; 11: 81–3.

29.

19.

Gunes F, Akbal E, Cakir E, Akyurek O, Altinbas M, Ozbek
M. Visfatin may be a novel marker for identifying stages of
essential hypertension in advanced age patients. Intern Med
2012; 51: 553–7.

de Zeeuw D, Gansevoort RT, Dullaart RPF, Jong PE.
Angiotensin II antagonism improves the lipoprotein profile in
patients with nephrotic syndrome. J Hypertens 1995; 13: S53–
8.

30.

20.

Wang P, Bai C, Xu QY, Xu TY, Su DF, Sassard J et al. Visfatin
is associated with lipid metabolic abnormalities in Lyon
hypertensive rats. Clin Exp Pharmacol Physiol 2010; 37: 894–9.

Lerch M, Teuscher U, Beissner P, Schneider M, Shaw SG,
Weidmann P. Effects of angiotensin II receptor blockade with
losartan on insulin sensitivity, lipid profile, and endothelin in
normotensive offspring of hypertensive parents. J Cardiovasc
Pharmacol 1998; 31: 576–80.

31.

21.

Olszanecka-Glinianowicz M, Kocełak P, Nylec M, Chudek
J, Zahorska-Markiewicz B. Circulating visfatin level and
visfatin/insulin ratio in obese women with metabolic
syndrome. Arch Med Sci 2012; 8: 214–8.

Kyvelou SMG, Vyssoulis GP, Karpanou EA, Adamopoulos DN,
Zervoudaki AI, Pietri PG et al. Effects of angiotensin II receptor
blockers on lipid profile: an open multidrug comparison trial.
Hellenic J Cardiol 2006; 47: 21–8.

32.

22.

Storka A, Vojtassako E, Mueller M, Kapiotas S, Haider DG,
Jungbauer A et al. Angiotensin inhibition stimulates PPARY
and the release of visfatin. Eur J Clin Invest 2008; 38: 820–6.

Hanefeld M, Abletshauer C. Effect of the angiotensin II receptor
antagonist valsartan on lipid profile and glucose metabolism in
patients with hypertension. J Int Med Res 2001; 29: 270–9.

33.

Saraç S, Saraç F, Tütüncüoglu P. Effects of telmisartan and
valsartan on insulin resistance, visfatin and adiponectin
levels in hypertensive patients with metabolic syndrome. Acta
Endocrinologica (Buc) 2008; 4: 23–32.

Barutçuoğlu B, Parıldar Z, Mutaf MI, Özmen D, Alioğlu E,
Habif S et al. Effect of telmisartan on vascular endothelium in
hypertensive and type 2 diabetic hypertensive patients. Turk J
Med Sci 2010; 40: 239–48.

34.

Kirk JK. Angiotensin II receptor antagonists: their place in
therapy. Am Fam Phys 1999; 59: 3140–8.

13.

Hammerstedt A, Pihlajamaki J, Rotter Sopasakis V, Gogg S,
Jansson PA, Laakso M et al. Visfatin is an adipokine, but it is
not regulated by thiazolidinediones. J Clin Endocrinol Metab
2006; 91: 1181–4.

14.

Haider DG, Schindler K, Schaller G, Prager G, Woltz M, Ludvik
B. Increased plasma visfatin concentrations in morbidly obese
subjects are reduced after gastric banding. J Clin Endocrinol
Metab 2006; 91: 1578–81.

15.

Berndt J, Kloting N, Kralisch S, Kovacs P, Fasshauer M, Schon
MR et al. Plasma visfatin concentrations and fat depot-specific
mRNA expression in humans. Diabetes 2005; 54: 2911–6.

16.

23.

62

